Network Pharmacology to Explore the Molecular Mechanisms of Prunella vulgaris for Treating Hashimoto’s Thyroiditis

Gan, Xiao‐Xiong; Zhong, Lin‐Kun; Shen, Fei; Feng, Jianhua; Li, Ya-yi; Li, Sijing; Cai, Wei; Xu, Bo

doi:10.3389/fphar.2021.700896

Cited by 28 publications

(22 citation statements)

References 42 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Edaravone is a drug that scavenges hydroxyl radicals [104], it acts on the STAT3/PI3K/Akt pathway to effectively improve autoimmune thyroiditis and has become an emerging drug for the treatment of HT [104]. PVmediated HMGB1 inhibition decreased the expression of pro-inflammatory cytokines and suppressed the HMGB1-TLR9 signaling pathway in, while downregulating the proportion of Th1, Th2 and Th17 cells in splenocyte, provides a potential therapeutic value for HT [81], the lignan component of PV has a strong affinity for the disease protein of HT, and quercetin has a strong affinity for serum thyroid peroxidase (TPO), further confirming that PV can effectively treat HT [100].…”

Section: Treatmentmentioning

confidence: 83%

See 1 more Smart Citation

Pathogenesis Markers of Hashimoto's Disease—A Mini Review

Jin¹,

Wang²,

Fan³

2022

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

Hashimoto's thyroiditis (HT) is the most common autoimmune disease involving the thyroid gland. HT often clinically manifest as hypothyroidism due to the destruction of thyroid cells mediated by humoral and cellular immunity. The pathogenesis of HT is a complex process in which environmental factors, hereditary inclination, trace elements immune factors, cytokines, and DNA and miRNA all play an important role. Herein, we summarize the precision factors involved in the pathogenesis of HT and offer an update over the past 5 years to provide a theoretical basis for further investigation of the relevant targets for HT treatment.

show abstract

Section: Treatmentmentioning

confidence: 83%

“…The most common way to control HT is to take levothyroxine (L-T4) to control the disease [100]. Longterm use of 1.6-1.8 mg per kg to achieve normal levels of thyrotropin in the body [21].…”

Section: Treatmentmentioning

confidence: 99%

Pathogenesis Markers of Hashimoto's Disease—A Mini Review

Jin¹,

Wang²,

Fan³

2022

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

show abstract

“…What’s more, there are few reports on the PI3K-Akt signaling pathway in HT. The literature suggests that Prunella vulgaris may play an anti-inflammatory role by regulating the PI3K-Akt signaling pathway, thus realizing the treatment of HT ( 39 ). but this study only draws the conclusion through bioinformatics analysis, and has no in vivo or in vitro evidence.…”

Section: Discussionmentioning

confidence: 99%

Identification of Long Noncoding RNAs Associated With the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated With Hashimoto’s Thyroiditis

Ding

Peng

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) play a significant role in cancer biology. This study aimed to determine the roles of lncRNAs in establishing the differences in clinical features between patients with papillary thyroid carcinoma (PTC) without Hashimoto’s thyroiditis (HT) and patients with PTC and HT. In the present study, we detected the differentially expressed lncRNAs between tumor tissues of patients with PTC with or without HT through lncRNA microarrays. The data were verified and analyzed through qRT-PCR, cell viability, cell cycle and bioinformatics analyses. We found that 1031 lncRNAs and 1338 mRNAs were abnormally expressed in 5 tissue samples of PTC complicated with HT [PTC/HT (+)] compared with 5 samples of PTC without HT [PTC/HT (-)]. Gene Ontology and pathway analyses of the mRNAs suggested that several biological processes and pathways, particularly immune system processes, were induced in the PTC/HT (+) tissues. Twenty lncRNAs were verified in 31 PTC/HT (+) and 64 PTC/HT (-) specimens by qRT-PCR, and the results were consistent with the microarray data. Specifically, ENST00000452578, a downregulated lncRNA in PTC/HT(+), was negatively correlated with the tumor size. Cell viability assays revealed that ENST00000452578 could inhibit cell proliferation. Our results indicate that lncRNAs and mRNAs play an important role in establishing the different clinical characteristics between patients with PTC/HT(+) and patients with PTC/HT(-), and might provide new insights from the perspective of RNA for obtaining a further understanding of the clinical features related to PTC with HT.

show abstract

“…R-language packages ‘ClusterProfiler' and ‘ http://org.Hs.eg.Db ' were used to analyze the enrichment of GO and KEGG to explore the underlying biological function (BP), cellular components (CC), and molecular function (MF) and signaling pathways. A p .adjust (FDR) < 0.05 was considered statistically significant [ 21 ]. The bubble chart and Circro circles for GO and KEGG results were visualized by the Sangerbox platform ( http://sangerbox.com/Tool ).…”

Section: Methodsmentioning

confidence: 99%

Molecular Mechanism of Epimedium Extract against Ischemic Stroke Based on Network Pharmacology and Experimental Validation

You

Xiang

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Ischemic stroke exhibits high morbidity, disability, and mortality, and treatments for ischemic stroke are limited despite intensive research. The potent neuroprotective benefits of Epimedium against ischemic stroke have gained lots of interest. Nevertheless, systematic research on the direct role and mechanisms of Epimedium in ischemic stroke is still lacking. Network pharmacology analysis coupled with experimental verification was utilized to systematically evaluate the potential pharmacological mechanism of Epimedium against ischemic stroke. The TCMSP database was used to mine the bioactive ingredients and Epimedium’s targets. The DrugBank, OMIM, and GeneCards databases were employed to identify potential targets of ischemic stroke. GO and KEGG pathway analyses were also carried out. The interaction between active components and hub targets was confirmed via molecular docking. An experimental ischemic stroke model was used to evaluate the possible therapeutic mechanism of Epimedium. As a result, 23 bioactive compounds of Epimedium were selected, and 30 hub targets of Epimedium in its function against ischemic stroke were identified, and molecular docking results demonstrated good binding. The IL-17 signaling pathway was revealed as a potentially significant pathway, with the NF-κB and MAPK/ERK signaling pathways being involved. Furthermore, in vivo experiments demonstrated that Epimedium treatment could improve neurological function and reduce infarct volume. Additionally, Epimedium reduced the activation of microglia and astrocytes in both the ischemic penumbra of the hippocampus and cerebral cortex following ischemic stroke. Western blot and RT–qPCR analyses demonstrated that Epimedium not only depressed the expression of IL-1β, TNF-α, IL-6, and IL-4 but also inhibited the NF-κB and MAPK/ERK signaling pathways. This study applied network pharmacology and in vivo experiment to explore possible mechanism of Epimedium’s role against ischemic stroke, which provides insight into the treatment of ischemic stroke.

show abstract

Network Pharmacology to Explore the Molecular Mechanisms of Prunella vulgaris for Treating Hashimoto’s Thyroiditis

Cited by 28 publications

References 42 publications

Pathogenesis Markers of Hashimoto's Disease—A Mini Review

Pathogenesis Markers of Hashimoto's Disease—A Mini Review

Identification of Long Noncoding RNAs Associated With the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated With Hashimoto’s Thyroiditis

Molecular Mechanism of Epimedium Extract against Ischemic Stroke Based on Network Pharmacology and Experimental Validation

Contact Info

Product

Resources

About